The U.S. Food and Drug Administration (FDA) recently approved a ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. Xeris Pharmaceuticals is marketing this new glucagon injection as GVOKE. GVOKE is the first glucagon product approved that can be administered via...
The U.S. Food and Drug Administration last month approved semaglutide oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. This is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected. GLP-1...
Practicing clinicians know all too well that often life intervenes into meticulously planned career path. Endocrine News shares a few tips on steps you can take if you have to be out of the office for a while. For Sarah Hart-Unger, MD, a pediatric endocrinologist at Joe DiMaggio Children’s Hospital at Memorial Healthcare System in...
Next month, the Endocrine Society’s Clinical Endocrinology Update will kick off in Miami, during which attendees will hear about the latest breakthroughs in patient care, as well as those cases that may prove difficult for clinicians. One such session is Lisa Tannock’s Meet-the-Professor presentation on Thursday, September 5, titled “Challenging Cases in Lipid Management.” Cardiovascular...
After the success of last year’s special issue to promote and highlight the Endocrine Society’s Clinical Endocrinology Update (CEU) program, we decided to make it an annual tradition. For the second year in a row, CEU will take place twice in the September on both the East and West Coasts — Sept. 5 – 7...
The advent of newer — often very expensive — drugs has driven up the cost of care for diabetes. But older, less expensive medications can often still get the job done. Treating diabetes with lower-cost drugs might not only help a patient’s pocketbook, they might benefit the patient’s health as well. That will be one...
As the government shutdown lingers into its second month, there have been numerous stories in the media about government employees going without their medications, including insulin. To ease some of that burden, three insulin manufacturers — Eli Lilly and Company, Novo Nordisk, and Sanofi — are providing outreach to insulin-dependent patients affected by the partial...
Aside from the chances of becoming addicted or even dying from an overdose, opioids have also proven damaging to the endocrine system. An awareness by both patients and physicians is a much-needed first step to combatting these often severe conditions. Opioids have been grabbing headlines for the past couple of years. They’ve become an epidemic,...
Next month, the Endocrine Society’s Clinical Endocrinology Update will kick off in Miami, during which attendees will hear about the latest breakthroughs in patient care, as well as those cases that may prove difficult for clinicians. One such session is Lisa Tannock’s Meet-the-Professor presentation on Thursday, September 5, titled “Challenging Cases in Lipid Management.” Cardiovascular...
After the success of last year’s special issue to promote and highlight the Endocrine Society’s Clinical Endocrinology Update (CEU) program, we decided to make it an annual tradition. For the second year in a row, CEU will take place twice in the September on both the East and West Coasts — Sept. 5 – 7...
